Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Oyster Point Pharma

Evaluate

Thumbnail
November 08, 2022

Makeover sees Viatris move further away from generics

The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.

Thumbnail
December 21, 2021

Aldeyra needs more Tranquility

A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.

Article image
Vantage logo
November 01, 2021

US FDA approval tracker: October 2021

Article image
Vantage logo
October 01, 2021

Go or no go? UCB bids to make a mark in psoriasis

Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.

Article image
Vantage logo
September 16, 2021

Aerie brushes off dry eye trial failure

Endpoints, schmendpoints.

Article image
Vantage logo
April 14, 2021

Bausch boosted ahead of eye spin-off

NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.

Article image
Vantage logo
May 11, 2020

Remember Chantix? It’s back – for dry eye disease

The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.

Article image
Vantage logo
April 10, 2019

Venture funding slowdown continues in first quarter of 2019

Venture funding drops again, but there’s no need to panic yet.

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up